What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2023-03-17 compared with 2022-03-10 · 80 added, 77 removed, 20 unchanged (89% of the section changed)

ProtoKinetix, Incorporated

(“ProtoKinetix,” “we,” “us,” “our,” or the “Company”) is a research and development

stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins,

trademarked as AAGPs ® .

The Company has recently been in the process of directing major efforts to the practical

side of commercial validation.

The commercial applications for AAGPs ® in large markets such as targeted health care solutions

are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring

AAGP ® to market.

was incorporated as RJV Network, Inc.

under the laws of the State of Nevada on December 23, 1999 for the primary purpose of developing

an internet-based listing site that would provide detailed commercial real estate property listings and related data.

In July 2003,

the Company entered into an assignment of license agreement with BioKinetix Research, Incorporated for the assignment of rights relating

to proprietary technologies of BioKinetix Research, Incorporated for the creation and commercialization of “superantibodies.”

On July 8, 2003, the Company changed its name to “ProtoKinetix, Incorporated.”

The Company’s

executive (or corporate) offices are located at 412 Mulberry Street, Marietta, Ohio 45750.

Our telephone number is (740) 434-5041

and our website is www.protokinetix.com .

Note Regarding Forward-Looking Statements

The information

discussed in this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as well as some statements in press releases

and some oral statements of the Company’s officers during presentations about the Company include “forward looking statements”

within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities

Exchange Act of 1934 (the “Exchange Act”).

All statements, other than statements of historical facts, included herein

and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition

opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements.

These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,”

ProtoKinetix, Incorporated (“ProtoKinetix,”

“we,” “us,” “our,” or the “Company”) is a research and development stage bio-technology

company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGPs ® .

The Company has recently been in the process of directing major efforts to the practical side of commercial validation.

The commercial

applications for AAGPs ® in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently

working with researchers, business leaders and advisors and commercial entities to bring AAGP ® to market.

ProtoKinetix was incorporated as RJV Network,

under the laws of the State of Nevada on December 23, 1999 for the primary purpose of developing an internet-based listing site that

would provide detailed commercial real estate property listings and related data.

In July 2003, the Company entered into an assignment

of license agreement with BioKinetix Research, Incorporated for the assignment of rights relating to proprietary technologies of BioKinetix

Research, Incorporated for the creation and commercialization of “superantibodies.” On July 8, 2003, the Company changed

its name to “ProtoKinetix, Incorporated.”

The Company’s executive (or corporate)

offices are located at 109 W Main St, Dalton, Ohio 44618.

Our telephone number is (330) 445-4971 and our website is www.protokinetix.com

Cautionary Note Regarding Forward-Looking

The information discussed in this Annual Report

on Form 10-K for the fiscal year ended December 31, 2022 as well as some statements in press releases and some oral statements of the

Company’s officers during presentations about the Company include “forward looking statements” within the meaning of

Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the

“Exchange Act”).

All statements, other than statements of historical facts, included herein and therein concerning,

among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our

financial position, business strategy and other plans and objectives for future operations, are forward looking statements.

These forward

looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,”

“project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,”

3 unchanged sentences

could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, among others:

capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;

plans to develop and commercialize products from the AAGP ® molecule;

testing of the AAGP ® molecule;

intellectual property position;

commercialization, marketing and manufacturing capabilities and strategy;

ability to retain key members of our senior management and key scientific consultants;

effects of competition;

potential tax liabilities resulting from conducting business in the United States and Canada;

effect of further sales or issuances of our common stock and the price and volume volatility of our common stock;

and our common

stock’s limited trading history.

future results will depend upon various other risks and uncertainties, including, but not limited to, those detailed in the section entitled

“Risk Factors” included elsewhere in this Annual Report.

All forward looking statements attributable to us or persons

acting on our behalf are expressly qualified in their entirety by the cautionary statements in this section and elsewhere in this Annual

Other than as required under securities laws, we do not assume a duty to update these forward looking statements, whether

as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

Recent Developments

In March 2020, the

World Health Organization declared coronavirus COVID-19 a global pandemic.

This contagious disease outbreak, which has continued to spread,

and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially

leading to an economic downturn.

date of this filing, the Company has regained a significant portion of its operational capacity and we continue to move forward with

our research goals.

Our supply of the patented AAGP® molecule has been manufactured and stored in the United States and we have adequate

inventory to carry out the projects currently underway.

The Company engages contract research organizations (CROs) located in both the

United States and Canada.

The CROs contracted by the Company for research projects have been able to meet milestone goals without disruption

due to the pandemic.

In January of 2020, Protokinetix signed a master supply agreement with University of Alberta that clears the way

for testing of additional patients in the Phase I clinical trials.

The global pandemic halted all work on clinical trials and research

testing for most of 2020.

Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;

Our plans to develop and commercialize products from the AAGP ® molecule;

Ongoing testing of the AAGP ® molecule;

Our intellectual property position;

Our commercialization, marketing and manufacturing capabilities and strategy;

Our ability to retain key members of our senior management and key scientific consultants;

The effects of competition;

Our potential tax liabilities resulting from conducting business in the United States and Canada;

The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock;

Our common stock’s limited trading history.

Finally, our future results will depend upon

various other risks and uncertainties, including, but not limited to, those detailed in the section entitled “Risk Factors”

included elsewhere in this Annual Report.

All forward looking statements attributable to us or persons acting on our behalf are

expressly qualified in their entirety by the cautionary statements in this section and elsewhere in this Annual Report.

as required under securities laws, we do not assume a duty to update these forward looking statements, whether as a result of new information,

subsequent events or circumstances, changes in expectations or otherwise.

In March 2020, the World Health Organization declared

coronavirus COVID-19 a global pandemic.

This contagious disease outbreak, which has continued to spread, and any related adverse public

health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic

As of the date of this filing, the Company

has regained a significant portion of its operational capacity and we continue to move forward with our research goals.

Our supply of

the patented AAGP® molecule has been manufactured and stored in the United States and we have adequate inventory to carry out the

projects currently underway.

The Company engages contract research organizations (CROs) located in both the United States and Canada.

The CROs contracted by the Company for research projects have been able to meet milestone goals without disruption due to the pandemic.

In January of 2020, Protokinetix signed a master supply agreement with University of Alberta that clears the way for testing of additional

patients in the Phase I clinical trials.

The global pandemic halted all work on clinical trials and research testing for most of 2020.

Phase I trials were able restart mid-year 2021 but new strains of covid continue to plague the US and Canada.

We cannot accurately predict a completion date of Phase I trials.

to monitor the status of the pandemic and will adjust our strategy accordingly in order to mitigate the impact on our research projects.

Company survived the adverse effects of the 2020 Covid-19 outbreak and as at December 31, 2021 continues to carry out operations including

raising funds for ongoing research and product development.

We cannot accurately predict

a completion date of Phase I trials.

We continue to monitor the status of the pandemic

and will adjust our strategy accordingly in order to mitigate the impact on our research projects.

The Company survived the adverse

effects of the 2020 Covid-19 outbreak and as at December 31, 2022 continues to carry out operations including raising funds for ongoing

research and product development.

On February 11, 2022, the Company held its

11 unchanged sentences

for the 2022 fiscal year.

During the year 2022 the Company developed an ophthalmic

formulation and completed efficacy testing in a dry eye formulation and various dosages.

Phase I clinical trials conducted by Dr.

Shapiro were reactivated but access to qualified patients has been slow and progress minimal since global pandemic.

The Company is making

a concerted effort to find strategic partners and is the impressive accumulation of research data to attract potential partners or buyers

of the Company.

Industry leaders in biochemistry and pharmaceuticals, both domestic and international, are potential partners.

Research and Development

Our business depends

on our ability to sponsor research and development activities.

For the year ended December 31, 2020, the Company incurred total

research and development expenses of $527,921.

For the year ended December 31, 2021, the Company incurred total research and development

expenses of $435,872.

In order to reach the Company’s goals of developing a marketable product, we will need to increase

the funding of our research and development activities which at this time is limited by our ability to raise money to fund the Company.

Our business depends on our ability to sponsor research

and development activities.

For the year ended December 31, 2021, the Company incurred total research and development expenses of

For the year ended December 31, 2022, the Company incurred total research and development expenses of $448,873.

In order to reach the Company’s goals of developing a marketable product, we will need to increase the funding of our research and

development activities which at this time is limited by our ability to raise money to fund the Company.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business